Literature DB >> 22695158

Prevalence of chronic Q fever in patients with a history of cardiac valve surgery in an area where Coxiella burnetii is epidemic.

Linda M Kampschreur1, Jan Jelrik Oosterheert, Andy I M Hoepelman, Peter J Lestrade, Nicole H M Renders, Peter Elsman, Peter C Wever.   

Abstract

Chronic Q fever develops in 1 to 5% of patients infected with Coxiella burnetii. The risk for chronic Q fever endocarditis has been estimated to be ≈ 39% in case of preexisting valvulopathy and is potentially even higher for valvular prostheses. Since 2007, The Netherlands has faced the largest Q fever outbreak ever reported, allowing a more precise risk estimate of chronic Q fever in high-risk groups. Patients with a history of cardiac valve surgery were selected for microbiological screening through a cardiology outpatient clinic in the area where Q fever is epidemic. Blood samples were analyzed for phase I and II IgG against C. burnetii, and if titers were above a defined cutoff level, C. burnetii PCR was performed. Chronic Q fever was considered proven if C. burnetii PCR was positive and probable if the phase I IgG titer was ≥ 1:1,024. Among 568 patients, the seroprevalence of C. burnetii antibodies (IgG titer greater than or equal to 1:32) was 20.4% (n = 116). Proven or probable chronic Q fever was identified among 7.8% of seropositive patients (n = 9). Valve characteristics did not influence the risk for chronic Q fever. Patients with chronic Q fever were significantly older than patients with past Q fever. In conclusion, screening of high-risk groups is a proper instrument for early detection of chronic Q fever cases. The estimated prevalence of chronic Q fever is 7.8% among seropositive patients with a history of cardiac valve surgery, which is substantially higher than that in nonselected populations but lower than that previously reported. Older age seems to increase vulnerability to chronic Q fever in this population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22695158      PMCID: PMC3416079          DOI: 10.1128/CVI.00185-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  27 in total

Review 1.  Natural history and pathophysiology of Q fever.

Authors:  D Raoult; Tj Marrie; Jl Mege
Journal:  Lancet Infect Dis       Date:  2005-04       Impact factor: 25.071

Review 2.  Q fever.

Authors:  Neil R Parker; Jennifer H Barralet; Alan Morton Bell
Journal:  Lancet       Date:  2006-02-25       Impact factor: 79.321

3.  Role of sex, age, previous valve lesion, and pregnancy in the clinical expression and outcome of Q fever after a large outbreak.

Authors:  Hervé Tissot-Dupont; Véronique Vaillant; Sylvie Rey; Didier Raoult
Journal:  Clin Infect Dis       Date:  2006-12-06       Impact factor: 9.079

4.  Real-time PCR with serum samples is indispensable for early diagnosis of acute Q fever.

Authors:  Peter M Schneeberger; Mirjam H A Hermans; Erik J van Hannen; Jeroen J A Schellekens; Alexander C A P Leenders; Peter C Wever
Journal:  Clin Vaccine Immunol       Date:  2009-12-23

Review 5.  The aging of the immune system.

Authors:  Daniela Weiskopf; Birgit Weinberger; Beatrix Grubeck-Loebenstein
Journal:  Transpl Int       Date:  2009-07-16       Impact factor: 3.782

Review 6.  Q fever.

Authors:  Hervé Tissot-Dupont; Didier Raoult
Journal:  Infect Dis Clin North Am       Date:  2008-09       Impact factor: 5.982

7.  Long-term outcome of Q fever endocarditis: a 26-year personal survey.

Authors:  Matthieu Million; Franck Thuny; Hervé Richet; Didier Raoult
Journal:  Lancet Infect Dis       Date:  2010-07-14       Impact factor: 25.071

8.  From acute Q fever to endocarditis: serological follow-up strategy.

Authors:  Cécile Landais; Florence Fenollar; Franck Thuny; Didier Raoult
Journal:  Clin Infect Dis       Date:  2007-04-04       Impact factor: 9.079

9.  Coxiella burnetii infection of aortic aneurysms or vascular grafts: report of 30 new cases and evaluation of outcome.

Authors:  E Botelho-Nevers; P-E Fournier; H Richet; F Fenollar; H Lepidi; C Foucault; A Branchereau; P Piquet; M Maurin; D Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-09       Impact factor: 3.267

10.  One-year follow-up of patients of the ongoing Dutch Q fever outbreak: clinical, serological and echocardiographic findings.

Authors:  G J M Limonard; M H Nabuurs-Franssen; G Weers-Pothoff; C Wijkmans; R Besselink; A M Horrevorts; P M Schneeberger; C A R Groot
Journal:  Infection       Date:  2010-09-21       Impact factor: 3.553

View more
  17 in total

1.  Histological characteristics of the abdominal aortic wall in patients with vascular chronic Q fever.

Authors:  Julia C J P Hagenaars; Olivier H J Koning; Ronald F F van den Haak; Bart A N Verhoeven; Nicole H M Renders; Mirjam H A Hermans; Peter C Wever; Robert Jan van Suylen
Journal:  Int J Exp Pathol       Date:  2014-06-23       Impact factor: 1.925

2.  Serological follow-up in patients with aorto-iliac disease and evidence of Q fever infection.

Authors:  J C J P Hagenaars; N H M Renders; A S van Petersen; S O A Shamelian; M G L de Jager-Leclercq; F L Moll; P C Wever; O H J Koning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-03-12       Impact factor: 3.267

3.  Dysregulation of serum gamma interferon levels in vascular chronic Q Fever patients provides insights into disease pathogenesis.

Authors:  Jeroen L A Pennings; Marjolein N T Kremers; Hennie M Hodemaekers; Julia C J P Hagenaars; Olivier H J Koning; Nicole H M Renders; Mirjam H A Hermans; Arja de Klerk; Daan W Notermans; Peter C Wever; Riny Janssen
Journal:  Clin Vaccine Immunol       Date:  2015-04-29

Review 4.  Antimicrobial therapies for Q fever.

Authors:  Gilbert J Kersh
Journal:  Expert Rev Anti Infect Ther       Date:  2013-09-27       Impact factor: 5.091

5.  Long-Term Serological Follow-Up of Acute Q-Fever Patients after a Large Epidemic.

Authors:  Cornelia C H Wielders; Joris A F van Loenhout; Gabriëlla Morroy; Ariene Rietveld; Daan W Notermans; Peter C Wever; Nicole H M Renders; Alexander C A P Leenders; Wim van der Hoek; Peter M Schneeberger
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

6.  Coxiella burnetii Epitope-Specific T-Cell Responses in Patients with Chronic Q Fever.

Authors:  Ann E Sluder; Anja Garritsen; Anja Scholzen; Guilhem Richard; Leonard Moise; Eva Hartman; Chantal P Bleeker-Rovers; Patrick M Reeves; Susan Raju Paul; William D Martin; Anne S De Groot; Mark C Poznansky
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

7.  Natural Exposure- and Vaccination-Induced Profiles of Ex Vivo Whole Blood Cytokine Responses to Coxiella burnetii.

Authors:  Susan Raju Paul; Anja Scholzen; Ghazel Mukhtar; Stephanie Wilkinson; Peter Hobson; Richard K Dzeng; Jennifer Evans; Jennifer Robson; Rowland Cobbold; Stephen Graves; Mark C Poznansky; Anja Garritsen; Ann E Sluder
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

8.  Vascular chronic Q fever: quality of life.

Authors:  J C J P Hagenaars; P C Wever; S O A Shamelian; A S Van Petersen; M Hilbink; N H M Renders; G L De Jager-Leclercq; F L Moll; O H J Koning
Journal:  Epidemiol Infect       Date:  2015-01-22       Impact factor: 4.434

9.  Long-term serological follow-up after primary Coxiella burnetii infection in patients with vascular risk factors for chronic Q fever.

Authors:  Sheila B Buijs; Sanne K Stuart; Jan Jelrik Oosterheert; Steffi Karhof; Andy I M Hoepelman; Nicole H M Renders; André S van Petersen; Chantal P Bleeker-Rovers; Peter C Wever; Olivier H J Koning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-02-10       Impact factor: 3.267

10.  Diagnosis of Coxiella burnetii infection: comparison of a whole blood interferon-gamma production assay and a Coxiella ELISPOT.

Authors:  Teske Schoffelen; Gijs J M Limonard; Chantal P Bleeker-Rovers; John J M Bouwman; Jos W M van der Meer; Marrigje Nabuurs-Franssen; Tom Sprong; Marcel van Deuren
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.